Protein Kinase C-ε Promotes Survival of Lung Cancer Cells by Suppressing Apoptosis through Dysregulation of the Mitochondrial Caspase Pathway*

The serine/threonine protein kinase C (PKC) has been implicated in the regulation of drug resistance and cell survival in many types of cancer cells. However, the one or more precise mechanisms remain elusive. In this study, we have identified and determined the mechanism by which PKC-ε, a novel PKC isoform, modulates drug resistance in lung cancer cells. Western blot analysis demonstrates that expression of PKC-ε, but not other PKC isoforms, is associated with the chemo-resistant phenotype of non-small cell lung cancer (NSCLC) cell lines. Northern blotting and nuclear run-on transcription analysis further reveals that the failure of expression of PKC-ε in the chemo-sensitive phenotype of small cell lung cancer (SCLC) cells results from transcriptional inactivation of the gene. Importantly, forced expression of PKC-ε in NCI-H82 human SCLC cells confers a significant resistance to the chemotherapeutic drugs, etoposide and doxorubicin. Resistance is characterized by a significant reduction in apoptosis in PKC-ε-expressing cells. Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochromec from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP). All of these events are blocked by PKC-ε expression. Furthermore, caspase-specific inhibitors, z-VAD-fmk and z-DEVD-fmk, significantly attenuate the accumulation of sub-G1population and block the PARP cleavage in response to etoposide. These results suggest that PKC-ε prevents cells from undergoing apoptosis through inhibition of the mitochondrial-dependent caspase activation, thereby leading to cell survival. Finally, down-regulation of PKC-ε expression by the antisense cDNA in NSCLC cells results in increased sensitivity to etoposide. Taken together, our findings suggest an important role for PKC-ε in regulating survival of lung cancer cells.

[1]  K. Shimamoto,et al.  Opening of mitochondrial KATP channel occurs downstream of PKC-ε activation in the mechanism of preconditioning , 2002 .

[2]  D. Terrian,et al.  Protein Kinase Cε Has the Potential to Advance the Recurrence of Human Prostate Cancer , 2002 .

[3]  A. Newton,et al.  Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. , 2001, Chemical reviews.

[4]  G. Evan,et al.  Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.

[5]  T. Kuroki,et al.  Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. , 2000, The Journal of biological chemistry.

[6]  P. Parker,et al.  Protein kinase C binding partners. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[7]  M. Lenardo,et al.  Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. , 2000, Journal of cell science.

[8]  W. Lang,et al.  A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. , 2000, Cancer research.

[9]  K. Suzuki,et al.  Proteolytic activation of protein kinase C delta and epsilon by caspase-3 in U937 cells during chemotherapeutic agent-induced apoptosis. , 1999 .

[10]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[11]  S. Anderson,et al.  Protein Kinase C δ Is Essential for Etoposide-induced Apoptosis in Salivary Gland Acinar Cells* , 1999, The Journal of Biological Chemistry.

[12]  S. Korsmeyer,et al.  Cell Death in Development , 1999, Cell.

[13]  W. May,et al.  A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis* , 1998, The Journal of Biological Chemistry.

[14]  A. W. Murray,et al.  Evidence That Protein Kinase Cε Mediates Phorbol Ester Inhibition of Calphostin C- and Tumor Necrosis Factor-α-induced Apoptosis in U937 Histiocytic Lymphoma Cells* , 1998, The Journal of Biological Chemistry.

[15]  G. Perletti,et al.  Protein kinase Cε is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway , 1998, Oncogene.

[16]  P. Parker,et al.  Loss of protein kinase C function induces an apoptotic response , 1998, Oncogene.

[17]  Z. Szallasi,et al.  Overexpression of Protein Kinase C Isoform but not δ in Human Interleukin-3–Dependent Cells Suppresses Apoptosis and Induces bcl-2 Expression , 1998 .

[18]  D. Mochly‐Rosen,et al.  A Selective ε-Protein Kinase C Antagonist Inhibits Protection of Cardiac Myocytes from Hypoxia-induced Cell Death* , 1997, The Journal of Biological Chemistry.

[19]  A. Fields,et al.  Atypical Protein Kinase C ι Protects Human Leukemia Cells against Drug-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[20]  G M Cohen,et al.  Caspases: the executioners of apoptosis. , 1997, The Biochemical journal.

[21]  M. Diaz-Meco,et al.  Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade , 1997, Molecular and cellular biology.

[22]  S. Baylin,et al.  Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  Y. Hannun,et al.  Apoptosis and the dilemma of cancer chemotherapy. , 1997, Blood.

[24]  W. Kolch,et al.  PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. , 1996, Oncogene.

[25]  N. Saijo,et al.  Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[26]  H. Mischak,et al.  Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. , 1996, Oncogene.

[27]  R. Casero,et al.  Differential transcription of the human spermidine/spermine N1-acetyltransferase (SSAT) gene in human lung carcinoma cells. , 1996, The Biochemical journal.

[28]  A. Basu,et al.  Oncogenic transformation alters cisplatin‐induced apoptosis in rat embryo fibroblasts , 1995, International journal of cancer.

[29]  A. Basu,et al.  Comparison of protein kinase C activity and isoform expression in cisplatin‐sensitive and ‐resistant ovarian carcinoma cells , 1995, International journal of cancer.

[30]  Y. Nishizuka.  Protein kinase C and lipid signaling for sustained cellular responses , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Volm,et al.  Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. , 1995, Anticancer research.

[32]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[33]  K. Longmuir,et al.  Phosphorylation, transbilayer movement, and facilitated intracellular transport of diacylglycerol are involved in the uptake of a fluorescent analog of phosphatidic acid by cultured fibroblasts. , 1985, The Journal of biological chemistry.

[34]  D. Ettinger,et al.  Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. A clinicopathologic study. , 1979, The American journal of medicine.

[35]  R. Rotem,et al.  Protein kinase C ε mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells , 2002 .

[36]  J. Hofmann.  Modulation of protein kinase C in antitumor treatment. , 2001, Reviews of physiology, biochemistry and pharmacology.

[37]  S. Cory,et al.  Life-or-death decisions by the Bcl-2 protein family. , 2001, Trends in biochemical sciences.

[38]  Paul J. Smith,et al.  Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction , 2000, Cancer Chemotherapy and Pharmacology.

[39]  M. Lutter,et al.  Biochemical pathways of caspase activation during apoptosis. , 1999, Annual review of cell and developmental biology.

[40]  S. Baylin,et al.  Transitions between lung cancer phenotypes--implications for tumor progression. , 1991, Cancer cells.

[41]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.